Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice

Autosomal dominant hypophosphatemic rickets (ADHR) is unique among the disorders involving Fibroblast growth factor 23 (FGF23) because individuals with R176Q/W and R179Q/W mutations in the FGF23 176RXXR179/S180 proteolytic cleavage motif can cycle from unaffected status to delayed onset of disease. This onset may occur in physiological states associated with iron deficiency, including puberty and pregnancy. To test the role of iron status in development of the ADHR phenotype, WT and R176Q-Fgf23 knock-in (ADHR) mice were placed on control or low-iron diets. Both the WT and ADHR mice receiving low-iron diet had significantly elevated bone Fgf23 mRNA. WT mice on a low-iron diet maintained normal serum intact Fgf23 and phosphate metabolism, with elevated serum C-terminal Fgf23 fragments. In contrast, the ADHR mice on the low-iron diet had elevated intact and C-terminal Fgf23 with hypophosphatemic osteomalacia. We used in vitro iron chelation to isolate the effects of iron deficiency on Fgf23 expression. We found that iron chelation in vitro resulted in a significant increase in Fgf23 mRNA that was dependent upon Mapk. Thus, unlike other syndromes of elevated FGF23, our findings support the concept that late-onset ADHR is the product of gene–environment interactions whereby the combined presence of an Fgf23-stabilizing mutation and iron deficiency can lead to ADHR.

[1]  Leah R. Padgett,et al.  Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. , 2011, The Journal of clinical endocrinology and metabolism.

[2]  E. Farrow,et al.  Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation. , 2010, The Journal of endocrinology.

[3]  W. Holzgreve,et al.  Diagnosis and treatment of iron-deficiency anaemia during pregnancy and postpartum , 2010, Archives of Gynecology and Obstetrics.

[4]  M. Gribaa,et al.  An autosomal dominant hypophosphatemic rickets phenotype in a Tunisian family caused by a new FGF23 missense mutation , 2010, Journal of Bone and Mineral Metabolism.

[5]  T. Fujita,et al.  Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. , 2009, Bone.

[6]  C. Frampton,et al.  FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. , 2009, The Journal of clinical endocrinology and metabolism.

[7]  E. Farrow,et al.  Initial FGF23-mediated signaling occurs in the distal convoluted tubule. , 2009, Journal of the American Society of Nephrology : JASN.

[8]  M. Doogue,et al.  Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia , 2009, Annals of clinical biochemistry.

[9]  W. Fraser,et al.  The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays , 2007, Annals of clinical biochemistry.

[10]  V. Nizet,et al.  Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). , 2007, The Journal of clinical investigation.

[11]  Siu L. Hui,et al.  FGF23 Concentrations Vary With Disease Status in Autosomal Dominant Hypophosphatemic Rickets , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  K. Okawa,et al.  Klotho converts canonical FGF receptor into a specific receptor for FGF23 , 2006, Nature.

[13]  L. Bonewald,et al.  Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism , 2006, Nature Genetics.

[14]  T. Strom,et al.  DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis , 2006, Nature Genetics.

[15]  Xi Jiang,et al.  Pathogenic role of Fgf23 in Hyp mice. , 2006, American journal of physiology. Endocrinology and metabolism.

[16]  K. Rosenblatt,et al.  Regulation of Fibroblast Growth Factor-23 Signaling by Klotho* , 2006, Journal of Biological Chemistry.

[17]  C. Cutler,et al.  Iron loading into ferritin can be stimulated or inhibited by the presence of cations and anions: a specific role for phosphate. , 2005, Journal of inorganic biochemistry.

[18]  S. Mooney,et al.  Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. , 2005, Endocrinology.

[19]  H. Tenenhouse Regulation of phosphorus homeostasis by the type iia na/phosphate cotransporter. , 2005, Annual review of nutrition.

[20]  Jerry Kaplan,et al.  Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization , 2004, Science.

[21]  M. Razzaque,et al.  Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. , 2004, Matrix biology : journal of the International Society for Matrix Biology.

[22]  C. Ohlsson,et al.  Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. , 2004, Endocrinology.

[23]  Y. Takeuchi,et al.  FGF‐23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  S. Fukumoto,et al.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. , 2003, The New England journal of medicine.

[25]  L. Quarles,et al.  Serum FGF23 Levels in Normal and Disordered Phosphorus Homeostasis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  K. Eckardt,et al.  Activation of the hypoxia‐inducible factor pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  C. Jun,et al.  Involvement of p38 MAP kinase during iron chelator-mediated apoptotic cell death. , 2002, Cellular immunology.

[28]  Y. Takeuchi,et al.  Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. , 2002, The Journal of clinical endocrinology and metabolism.

[29]  T. Yoneya,et al.  Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. , 2002, Endocrinology.

[30]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[31]  T. Strom,et al.  Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. , 2001, Kidney international.

[32]  S. Takeda,et al.  Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  T. Meitinger,et al.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23 , 2000, Nature Genetics.

[34]  M. Shiraki,et al.  Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy. , 1998, Endocrine journal.

[35]  T. Kobayashi,et al.  Saccharated ferric oxide (SFO)-induced osteomalacia: in vitro inhibition by SFO of bone formation and 1,25-dihydroxy-vitamin D production in renal tubules. , 1997, Bone.

[36]  M. Econs,et al.  Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. , 1997, The Journal of clinical endocrinology and metabolism.

[37]  G. Semenza,et al.  Structural and functional analysis of hypoxia-inducible factor 1. , 1997, Kidney international.

[38]  K. Bitar,et al.  Regulation of smooth muscle contraction in rabbit internal anal sphincter by protein kinase C and Ins(1,4,5)P3. , 1991, The American journal of physiology.

[39]  W. Goodman,et al.  Transferrin enhances the antiproliferative effect of aluminum on osteoblast-like cells. , 1991, The American journal of physiology.

[40]  W. Goodman,et al.  Characterization of the transferrin receptor in UMR-106-01 osteoblast-like cells. , 1990, Endocrinology.

[41]  R. Morris,et al.  Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. , 1989, The Journal of clinical investigation.

[42]  M. Drezner,et al.  Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[43]  Y. Ohira,et al.  Effects of dietary iron deficiency on muscle fiber characteristics and whole-body distribution of hemoglobin in mice. , 1983, The Journal of nutrition.

[44]  F. Glorieux,et al.  Relation between hypomineralized periosteocytic lesions and bone mineralization in vitamin D-resistant rickets , 1983, Calcified Tissue International.

[45]  Harrison He,et al.  Familial hypophosphatemic rickets showing autosomal dominant inheritance. , 1971 .

[46]  D. Burr,et al.  Morphological Assessment of Basic Multicellular Unit Resorption Parameters in Dogs Shows Additional Mechanisms of Bisphosphonate Effects on Bone , 2009, Calcified Tissue International.

[47]  G. Tompkins,et al.  The Effects of Dietary Ferric Iron and Iron Deprivation on the Bacterial Composition of the Mouse Intestine , 2001, Current Microbiology.

[48]  J. Bianchine,et al.  Familial hypophosphatemic rickets showing autosomal dominant inheritance. , 1971, Birth defects original article series.